MX2023006380A - Anticuerpos anti-bcma unicamente de cadena pesada. - Google Patents
Anticuerpos anti-bcma unicamente de cadena pesada.Info
- Publication number
- MX2023006380A MX2023006380A MX2023006380A MX2023006380A MX2023006380A MX 2023006380 A MX2023006380 A MX 2023006380A MX 2023006380 A MX2023006380 A MX 2023006380A MX 2023006380 A MX2023006380 A MX 2023006380A MX 2023006380 A MX2023006380 A MX 2023006380A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- heavy chain
- bcma
- bcma heavy
- compositions
- Prior art date
Links
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 abstract 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 1
- 208000037914 B-cell disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Anticuerpos anti-BCMA únicamente de cadena pesada (HCAb) y descritos, junto con métodos para producir dichos anticuerpos, composiciones, incluidas composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos de linfocitos B caracterizados por la expresión de BCMA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662437588P | 2016-12-21 | 2016-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006380A true MX2023006380A (es) | 2023-06-14 |
Family
ID=60972501
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007379A MX2019007379A (es) | 2016-12-21 | 2017-12-21 | Anticuerpos anti-bcma unicamente de cadena pesada. |
MX2023006380A MX2023006380A (es) | 2016-12-21 | 2019-06-19 | Anticuerpos anti-bcma unicamente de cadena pesada. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019007379A MX2019007379A (es) | 2016-12-21 | 2017-12-21 | Anticuerpos anti-bcma unicamente de cadena pesada. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11434299B2 (es) |
EP (2) | EP4215548A1 (es) |
JP (2) | JP7254699B2 (es) |
KR (2) | KR102633423B1 (es) |
CN (2) | CN110431151B (es) |
AU (1) | AU2017382251A1 (es) |
BR (1) | BR112019012354A2 (es) |
CA (1) | CA3047419A1 (es) |
IL (2) | IL300729A (es) |
MX (2) | MX2019007379A (es) |
WO (1) | WO2018119215A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109843325B (zh) | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
CN117866097A (zh) | 2017-06-20 | 2024-04-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
CA3086187A1 (en) * | 2017-12-20 | 2019-06-27 | Poseida Therapeutics, Inc. | Vcar compositions and methods for use |
JP7486421B2 (ja) | 2017-12-22 | 2024-05-17 | テネオバイオ, インコーポレイテッド | Cd22に結合する重鎖抗体 |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
MA53168A (fr) | 2018-07-19 | 2021-05-26 | Regeneron Pharma | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations |
SG11202102713TA (en) | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
CA3100232A1 (en) * | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
US20220042038A1 (en) * | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
JOP20210323A1 (ar) | 2019-06-14 | 2023-01-30 | Teneobio Inc | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 |
CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
UY39191A (es) | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
CR20230149A (es) | 2020-04-29 | 2023-05-25 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539) |
JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 |
CN112538115B (zh) * | 2020-12-08 | 2022-05-03 | 博奥信生物技术(南京)有限公司 | 一种抗人bcma纳米抗体及其制备方法和应用 |
CN112592405B (zh) * | 2020-12-08 | 2022-05-03 | 博奥信生物技术(南京)有限公司 | 抗人bcma纳米抗体及其制备方法和应用 |
CN117924497A (zh) * | 2021-03-22 | 2024-04-26 | 浙江纳米抗体技术中心有限公司 | 一种靶向bcma的纳米抗体及其应用 |
CN115521381A (zh) * | 2021-06-24 | 2022-12-27 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
DE60042617D1 (de) | 1999-01-07 | 2009-09-03 | Zymogenetics Inc | Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2 |
CA2383154C (en) | 1999-08-17 | 2013-04-30 | Biogen, Inc. | Baff receptor (bcma), an immunoregulatory agent |
AU6232899A (en) | 1999-10-06 | 2001-05-10 | Campina Melkunie B.V. | Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
US20020086018A1 (en) | 2000-05-12 | 2002-07-04 | Theill Lars Eyde | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI |
EP2301971A1 (en) | 2001-02-20 | 2011-03-30 | ZymoGenetics, L.L.C. | Antibodies that bind both BCMA and TACI |
CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
CN100453556C (zh) | 2003-10-16 | 2009-01-21 | 麦克罗梅特股份公司 | 多特异性的去免疫化cd3结合物 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
AU2005250499B2 (en) | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
MX2007000921A (es) | 2004-07-22 | 2007-11-09 | Univ Erasmus Medical Ct | Moleculas de union. |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
AR057807A1 (es) | 2005-09-12 | 2007-12-19 | Novimmune Sa | Formulaciones de anticuerpo anti-cd3 |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
EP1952150B1 (en) | 2005-11-23 | 2016-12-14 | Genentech, Inc. | Methods and compositions related to b cell assays |
TW200738750A (en) | 2005-12-06 | 2007-10-16 | Domantis Ltd | Ligands and methods of use therefor |
WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
EP3461842A1 (en) | 2007-04-03 | 2019-04-03 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
TR201816277T4 (tr) | 2007-04-03 | 2018-11-21 | Amgen Res Munich Gmbh | Çapraz-tür-spesifik bağlama alanı. |
CA2682626A1 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
US8703485B2 (en) | 2007-06-01 | 2014-04-22 | Omt, Inc. | Germ cells having inactivated endogenous immunoglobulin genes, and transgenic animals derived therefrom |
MX369784B (es) * | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
RS54900B1 (sr) | 2008-10-01 | 2016-10-31 | Amgen Res (Munich) Gmbh | Interspecijski specifično psmaxcd3 bispecifično jednolančano antitelo |
US9260522B2 (en) | 2008-10-01 | 2016-02-16 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
KR101837053B1 (ko) | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
WO2010104949A2 (en) * | 2009-03-10 | 2010-09-16 | Biogen Idec Ma Inc. | Anti-bcma antibodies |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
JP2014500879A (ja) | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
EP3415531B1 (en) * | 2011-05-27 | 2023-09-06 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) - binding proteins |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
AU2013340799B2 (en) | 2012-11-01 | 2018-08-09 | Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) | An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
CA2929256C (en) | 2013-11-04 | 2022-04-26 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-bcma嵌合抗原受體治療癌症 |
CN107108738A (zh) | 2014-07-25 | 2017-08-29 | 西托姆克斯治疗公司 | 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法 |
MA39070A1 (fr) | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
CN105457024B (zh) * | 2014-10-13 | 2021-03-16 | 李小彦 | 抗butyrophilin-3人源化抗体及其使用 |
IL251010B2 (en) | 2014-10-22 | 2024-01-01 | Crescendo Biologics Ltd | transgenic mice |
LT3230321T (lt) | 2014-12-12 | 2019-12-10 | Bluebird Bio Inc | Bcma chimeriniai antigeno receptoriai |
GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
JP6827426B2 (ja) | 2015-05-20 | 2021-02-10 | ヤンセン バイオテツク,インコーポレーテツド | 軽鎖アミロイドーシス及びその他のcd38陽性血液悪性疾患の治療のための抗cd38抗体 |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
MA53750A (fr) | 2015-08-17 | 2021-09-15 | Janssen Pharmaceutica Nv | Anticorps anti-bcma, molécules de liaison d'antigène bispécifiques qui se lient au bcma et cd3 et leurs utilisations |
AU2016352676A1 (en) | 2015-11-10 | 2018-05-31 | University Medical Center Hamburg - Eppendorf | ANTIGEN-binding polypeptides directed against CD38 |
KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
MX2019002256A (es) | 2016-08-24 | 2019-10-09 | Teneobio Inc | Animales transgenicos no humanos que producen anticuerpos modificados solo de cadena pesada. |
CN109843325B (zh) | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
CN117866097A (zh) | 2017-06-20 | 2024-04-12 | 特尼奥生物股份有限公司 | 仅有重链的抗bcma抗体 |
EP3642236A1 (en) | 2017-06-20 | 2020-04-29 | TeneoOne, Inc. | Anti-bcma heavy chain-only antibodies |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
JP2021508479A (ja) | 2017-12-27 | 2021-03-11 | テネオバイオ, インコーポレイテッド | ヘテロ二量体特異的抗体上のcd3デルタ及びcd3イプシロン |
CR20230149A (es) | 2020-04-29 | 2023-05-25 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539) |
-
2017
- 2017-12-21 KR KR1020197020979A patent/KR102633423B1/ko active IP Right Grant
- 2017-12-21 WO PCT/US2017/067870 patent/WO2018119215A1/en active Application Filing
- 2017-12-21 EP EP23159815.2A patent/EP4215548A1/en active Pending
- 2017-12-21 CN CN201780079499.1A patent/CN110431151B/zh active Active
- 2017-12-21 KR KR1020237011552A patent/KR20230052309A/ko not_active Application Discontinuation
- 2017-12-21 IL IL300729A patent/IL300729A/en unknown
- 2017-12-21 CN CN202310141159.4A patent/CN116284402A/zh active Pending
- 2017-12-21 IL IL267485A patent/IL267485B2/en unknown
- 2017-12-21 AU AU2017382251A patent/AU2017382251A1/en active Pending
- 2017-12-21 US US16/472,173 patent/US11434299B2/en active Active
- 2017-12-21 MX MX2019007379A patent/MX2019007379A/es unknown
- 2017-12-21 BR BR112019012354A patent/BR112019012354A2/pt unknown
- 2017-12-21 CA CA3047419A patent/CA3047419A1/en active Pending
- 2017-12-21 JP JP2019534110A patent/JP7254699B2/ja active Active
- 2017-12-21 EP EP17829547.3A patent/EP3559035A1/en active Pending
-
2019
- 2019-06-19 MX MX2023006380A patent/MX2023006380A/es unknown
-
2022
- 2022-06-29 US US17/853,794 patent/US20230045100A1/en active Pending
-
2023
- 2023-02-09 JP JP2023018187A patent/JP2023071684A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230045100A1 (en) | 2023-02-09 |
WO2018119215A9 (en) | 2018-11-22 |
JP2023071684A (ja) | 2023-05-23 |
JP2020505001A (ja) | 2020-02-20 |
KR20230052309A (ko) | 2023-04-19 |
JP7254699B2 (ja) | 2023-04-10 |
WO2018119215A1 (en) | 2018-06-28 |
EP4215548A1 (en) | 2023-07-26 |
CN116284402A (zh) | 2023-06-23 |
IL267485B1 (en) | 2023-09-01 |
BR112019012354A2 (pt) | 2019-11-26 |
RU2019122880A (ru) | 2021-01-22 |
KR102633423B1 (ko) | 2024-02-06 |
CN110431151B (zh) | 2023-07-18 |
MX2019007379A (es) | 2019-09-18 |
IL267485B2 (en) | 2024-01-01 |
CN110431151A (zh) | 2019-11-08 |
AU2017382251A1 (en) | 2019-07-11 |
IL300729A (en) | 2023-04-01 |
RU2019122880A3 (es) | 2021-04-28 |
US11434299B2 (en) | 2022-09-06 |
EP3559035A1 (en) | 2019-10-30 |
US20190352412A1 (en) | 2019-11-21 |
IL267485A (en) | 2019-08-29 |
CA3047419A1 (en) | 2018-06-28 |
KR20190117489A (ko) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006380A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
ZA201908214B (en) | Anti-bcma heavy chain-only antibodies | |
MX2019015563A (es) | Anticuerpos anti-bcma unicamente de cadena pesada. | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
MY191581A (en) | Anti-pd-1 antibodies | |
NZ737399A (en) | Ccr2 modulators | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
SG10201901707QA (en) | Antibodies targeting b-cell maturation antigen and methods of use | |
NZ731789A (en) | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
TW201613893A (en) | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine | |
PH12020550964A1 (en) | Heavy chain antibodies binding to cd22 | |
PH12018500379A1 (en) | Biopharmaceutical compositions | |
PH12016501547A1 (en) | Anti-il-13/il-17 bispecific antibodies and uses thereof | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
CR20220656A (es) | Unión de anticuerpos multiespecíficos a bcma | |
MX2017012342A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades,. | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. |